Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Cryofocus Medtech (Shanghai) / Equity Capital Markets

<ul>
<li>Cryofocus Medtech is a China based medical device company with a focus on cryoablation. The company is look to raise $50-100m to list in Hong Kong.</li>
<li>We take a quick look at Cryofocus' key products, including AF cryoablation system and bladder cryoablation system.</li>
<li>We think its products are not impressive. Neither does its investor line-ups and management team impress us much.</li>
</ul>


Cryofocus Medtech is a China based medical device company with a focus on cryoablation. The company is look to raise $50-100m to list in Hong Kong.
We take a quick look at Cryofocus' key products, including AF cryoablation system and bladder cryoablation system.
We think its products are not impressive. Neither does its investor line-ups and management team impress us much.


Cryofocus Medtech (康灃生物科技) Pre-IPO: Unimpressive Fundamentals